Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Accumulated OCI

Accumulated other comprehensive income: unrealized gains and losses, such as currency translation, recorded outside net income.

Seer, Inc.NASDAQ: SEER

Accumulated OCI · Q1 FY2026 · quarter ended Mar 2026

Accumulated OCI turns negative

Q1 FY2026 Accumulated OCI was -$64K, compared with $305K a year earlier.

Context

  • Accumulated OCI amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
  • Accumulated OCI increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether Accumulated OCI keeps falling in the next quarterly balance sheet after a -121.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$64K-113.9% QoQ
Last fiscal yearDec 2025
$459K+237.5% YoY
Year agoMar 2025
$305K-121.0% since
Accumulated OCI past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-121.0%——
1 year+237.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accumulated OCI history

USD · from the balance sheet

Latest · FY2025
459K USD
Year-over-year change
+237.5%

Accumulated OCI vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so Accumulated OCI is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -121.0% is the 9th highest of 16, against a peer median of -119.9%.
  • Accumulated OCI amounts to 0.0% of total assets for SEER, versus a peer median of 0.0%.
SEER Competitors
Accumulated OCI for SEER and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PHVSPharvaris N.V.Sep 2026€56.99M EUR+20.5%+35.7%19.3%
CGEMCullinan Therapeutics, Inc.Mar 2026$127K USD-74.9%—0.0%
MLYSMineralys Therapeutics, Inc.Jun 2026$0 USD——0.0%
STTKShattuck Labs, Inc.Mar 2026$0 USD-100.0%—0.0%
MOLNMolecular Partners AGMar 2026CHF 0 CHF——0.0%
SANASana Biotechnology, Inc.Mar 2026-$2K USD——0.0%
ANTXAN2 Therapeutics, Inc.Mar 2026-$5K USD-110.4%—0.0%
LYELLyell Immunopharma, Inc.Mar 2026-$9K USD-105.7%—0.0%
PEPGPepGen Inc.Mar 2026-$59K USD-168.2%—0.0%
SEERSeer, Inc.Mar 2026-$64K USD-121.0%—0.0%
MNOVMediciNova, Inc.Mar 2026-$128.13K USD+1.5%—0.3%
NKTXNkarta, Inc.Mar 2026-$130K USD-119.9%—0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026-$133K USD-1050.0%—0.1%
NRIXNurix Therapeutics, Inc.Aug 2026-$210K USD-276.5%—0.0%
ORICORIC Pharmaceuticals, Inc.Mar 2026-$290K USD-238.8%—0.1%
CCCCC4 Therapeutics, Inc.Mar 2026-$322K USD-848.8%—0.1%
QSIQuantum-Si incorporatedMar 2026-$382K USD-19000.0%—0.2%
GLUEMonte Rosa Therapeutics, Inc.Mar 2026-$4.75M USD-42.6%—0.6%
KYMRKymera Therapeutics, Inc.Jun 2026-$7.16M USD-2665.2%—0.4%
Peer median (excluding SEER) —-119.9%+35.7%0.0%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents232.81M53.21M32.5M40.75M47.29M
Short-term Investments167.26M368.03M283.73M195.66M138.61M
Net Receivables4.14M7.02M6.72M6.23M5.95M
Inventory4.15M4.63M4.49M7.44M7.8M
Other Current Assets02.1M3.08M3.25M1.89M
Total Current Assets411.7M434.98M330.51M253.32M201.53M
Property, Plant & Equipment (Net)33.23M46.41M47.37M41.37M35.24M
Goodwill00000
Intangible Assets00000
Long-term Investments93.19M5.16M56.86M63.1M54.69M
Tax Assets00000
Other Non-current Assets1.03M1.38M1.53M8.81M4.62M
Total Non-current Assets127.44M52.95M105.76M113.27M94.55M
Total Assets539.14M487.93M436.27M366.6M296.08M
Account Payables3.79M2.1M1.37M4.62M5.61M
Short-term Debt002.3M2.31M0
Tax Payables457K335K501K471K0
Deferred Revenue376K133K206K408K341K
Other Current Liabilities4.73M6.35M2.73M1.54M5.63M
Total Current Liabilities13.42M12.58M13.22M15.33M15.69M
Long-term Debt000021.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities341K320K179K48K8K
Total Non-current Liabilities22.8M28.35M26.14M23.7M21.09M
Total Liabilities36.22M40.94M39.37M39.03M36.78M
Common Stock1K1K1K1K1K
Retained Earnings(126.53M)(219.5M)(305.77M)(392.37M)(465.97M)
Accumulated OCI(536K)(1.25M)(192K)136K459K
Other Stockholders Equity00000
Minority Interest00000
Total Equity502.92M446.99M396.9M327.57M259.31M
Total Debt23.32M29.87M28.26M25.96M23.65M
Net Debt(209.49M)(23.33M)(4.24M)(14.79M)(23.63M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.